Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,088 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bladder Tumor Clear all
Active, not recruiting Phase 2 Interventional

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

NCT07414992
View directory record Official record
Conditions
Bladder Urothelial Carcinoma
Interventions
Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab, Radical cystectomy
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Recruiting Not applicable Interventional

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

NCT07187063
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
UroAmp Test (Convergent Genomics, Inc.)
Diagnostic Test
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 10, 2026, 10:03 AM EDT
Recruiting Phase 2Phase 3 Interventional

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

NCT06493552
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Interventions
SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin
Drug
Lead sponsor
Vasgene Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 10, 2026, 10:03 AM EDT
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

NCT02092948
View directory record Official record
Conditions
Prostate Cancer, Pancreatic Cancer, Bladder Cancer
Interventions
[124I] PSCA-Minibody PET/CT imaging of the whole body
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 10, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

NCT05241340
View directory record Official record
Conditions
Urothelial Carcinoma Bladder
Interventions
Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

NCT00880334
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer
Interventions
Docetaxel, vandetanib, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

NCT01259063
View directory record Official record
Conditions
Bladder Cancer
Interventions
Everolimus and Intravesical Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 10, 2026, 10:03 AM EDT
Completed No phase listed Observational

Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer

NCT01776138
View directory record Official record
Conditions
Bladder Cancer
Interventions
Collect Blood and Survey Instruments
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 10, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614
View directory record Official record
Conditions
Nonmuscle-invasive Bladder Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT03693014
View directory record Official record
Conditions
Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Interventions
Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Radiation · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Early Phase 1 Interventional

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

NCT02646319
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 10, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

NCT07061964
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
165
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 130 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy

NCT03469362
View directory record Official record
Conditions
Bladder Cancer
Interventions
Extracorporeal Urinary Diversion, Intracorporal Urinary Diversion
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 10, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

NCT03915405
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
KHK2455, Avelumab
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
St. Petersburg, Florida • Iowa City, Iowa • Santa Fe, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 10, 2026, 10:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

NCT03498196
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
Interventions
Avelumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 10, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 10, 2026, 10:03 AM EDT
Recruiting Not applicable Interventional

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

NCT06394869
View directory record Official record
Conditions
Hematuria - Cause Not Known
Interventions
Cxbladder Triage Plus
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years to 88 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

NCT04375813
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
eRapa, Placebos
Drug
Lead sponsor
Robert Svatek
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

NCT00003376
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 10, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

NCT03106610
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 10, 2026, 10:03 AM EDT